Experience with the use of janus kinase inhibitors in the treatment of COVID-19 in patients in Volgograd

The new coronavirus infection (COVID-19) is characterized by high morbidity and mortality. The main approach to COVID-19 therapy should be the proactive administration of treatment before the development of a complete symptom complex of life-threatening conditions, including acute respiratory distress syndrome. The use of a selective and reversible inhibitor of janus kinase 1 and 2 prevents viral endocytosis, reduces excessive inflammatory response. The purpose of the study - to evaluate the effectiveness of the use of the Janus kinase inhibitor of the drug Baricitinib (Olumiant, manufacturer Lilly del Caribe Inc., Spain) in the treatment of patients with moderate COVID-19 in a hospital setting. During the clinical use of Baricitinib, significant positive changes were obtained compared with the initial level of vital signs and laboratory data. Significant positive changes in the following indicators were obtained: oxygen saturation increased (from 95.3 ± 4.0 to 97.5 ± 3.2 %, p = 0.011), body temperature decreased (from 37.3 ± 0.7 to 36.7 ± 0.5 °C, p = 0.000), C-reactive protein decreased (from 47.1 ± 46.0 to 32.5 ± 41.7 g/l, p = 0.010), the number of platelets increased (from 178.0 ± 59.5 to 249.5 ± 84.5; p = 0.000), when assessing the condition of patients in points on the NEWS-2 scale positive dynamics (from 1.6 ± 1.2 to 1.1 ± 1.3, p = 0.001). The level of C-reactive protein increased simultaneously with an increase in interleukin-6, an increase to 200.0 ± 6.2 pg/ml was recorded. The positive dynamics is an increase in the number of lymphocytes to 2.0 • 10⁹/l. By the end of inpatient treatment, ferritin levels had normalized to reference values of 27.7±2.1 mmol/l and D-dimer to the upper limit of normal. Positive dynamics of changes on the CT scan of the chest organs in the form of a decrease in infiltration. According to the combination of changes in clinical, laboratory signs and CT scan results, the therapy of patients was effective.

1. Number of COVID-19 cases reported to WHO. URL: https://covid19.who.int/.

2. Nasonov E. L. Coronavirus disease 2019 (COVID-19): reflections of a Rheumatologist. Naucho-prakticheskaya revmatologiya = Scientific and practical rheumatology. 2020; 58 (2): 123-132. doi: 10.14412/1995-4484-2020-123-132 (In Russ.).

3. Mishinova S. A., Zhuravkov A. A., Zhuravko V. K. The appointment of officially prohibited medicines and the use of medicines in violation of the instructions for use: focus on COVID-19. Kachestvennaya klinicheskaya praktika = Qualitative Clinical Practice. 2020; S4: 120-129. doi: 10.37489/2588-0519-2020-S4-120-129 (In Russ.).

4. Cantini F., Niccjli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Journal of Infection. 2020; 81 (2): 318-356. doi: 10.1016/j.jinf.2020.04.017.

5. Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 16 (18.08.2022) (approved by the Ministry of Health of Russia). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf (accessed: 25.04.2023) (In Russ.).

6. Choy E. N. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019; 58 (6): 953-962.

7. Zagrebneva A. I., Baryakh E. A., Zhelnova E. I., Poteshkina N. G. et al. Baricitinib in the treatment of patients with COVID-19: review of international data and analysis of the results of clinical application experience in the Russian population. Gospitalnaya meditsina: nauka i praktika = Hospital Medicine: Science and Practice. 2021; 4 (3): 60-67.

8. Olumiant: instructions for the medical use of the drug. URL: https://www.rlsnet.ru/drugs/olumiant-80014?ysclid=LGVZS7CF65817329017DISAPPROACH25.04.2023 (In Russ.).

9. Cantini F., Niccoli L., Nannini C., Matarrese D., Di Natale M. E., Lotti P., Aquilini D., Landini G., Cimolato B., Di Pietro M. A., Trezzi M., Stobbione P., Frausini G., NavarraA., Nicastri E., Sotgiu G., Goletti D. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. Journal of Infection. 2020; 81 (4): 647-679. doi: 10.1016/j.jinf.2020.06.052 (In Russ.).

10. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. URL: https://aix-scientifics.de/en/helsinki13.html.